Literature DB >> 3341836

High-dose furosemide in the treatment of refractory congestive heart failure.

P G Gerlag1, J J van Meijel.   

Abstract

Thirty-five patients with severe chronic congestive heart failure that was refractory to conventional therapy were given high dosages of furosemide (250 to 4000 mg/d) because of significantly reduced renal function (mean endogenous creatinine clearance, 0.53 mL/s/1.73 m2 [32 mL/min/1.73 m2]). Natriuresis, weight reduction (mean, 11 kg), and relief of symptoms were achieved in all patients. The mean survival after the start of the high-dose furosemide therapy was 11.3 months (range, 0.5 to 36 months) (n = 35). When this therapy eventually failed, long-term intermittent hemofiltration was performed in eight selected cases, further prolonging survival (mean, 3.0 months). High-dose furosemide therapy and hemofiltration improved the quality of life and prolonged survival. The use of diuretics in congestive heart failure should therefore include treatment with high-dose furosemide, which is effective and can be given over a long period without serious side effects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3341836

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  15 in total

Review 1.  Diuretic resistance in heart failure.

Authors:  Srinivas Iyengar; William T Abraham
Journal:  Curr Heart Fail Rep       Date:  2006-04

Review 2.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 3.  Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships.

Authors:  D A Sica; T W Gehr
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

4.  Zebrafish heart failure models for the evaluation of chemical probes and drugs.

Authors:  Cheng-Chen Huang; Aaron Monte; James M Cook; Mohd Shahjahan Kabir; Karl P Peterson
Journal:  Assay Drug Dev Technol       Date:  2013 Nov-Dec       Impact factor: 1.738

Review 5.  Severe heart failure in the elderly: potential benefits of high-dose and continuous infusion diuretics.

Authors:  Patricia A Howard; Marvin I Dunn
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 6.  Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.

Authors:  J Malcom O Arnold; Jonathan G Howlett; Paul Dorian; Anique Ducharme; Nadia Giannetti; Haissam Haddad; George A Heckman; Andrew Ignaszewski; Debra Isaac; Philip Jong; Peter Liu; Elizabeth Mann; Robert S McKelvie; Gordon W Moe; John D Parker; Anna M Svendsen; Ross T Tsuyuki; Kelly O'Halloran; Heather J Ross; Vivek Rao; Errol J Sequeira; Michel White
Journal:  Can J Cardiol       Date:  2007-01       Impact factor: 5.223

Review 7.  A perspective on diuretic resistance in chronic congestive heart failure.

Authors:  Niel Shah; Raef Madanieh; Mehmet Alkan; Muhammad U Dogar; Constantine E Kosmas; Timothy J Vittorio
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-07-20

Review 8.  Risks and benefits of the treatment of heart failure. Current status.

Authors:  J F Moran
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

Review 9.  Mechanisms and management of diuretic resistance in congestive heart failure.

Authors:  L K M De Bruyne
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

Review 10.  Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?

Authors:  G Michael Felker; Christopher M O'Connor; Eugene Braunwald
Journal:  Circ Heart Fail       Date:  2009-01       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.